Journal of Translational Autoimmunity · 2024 · 10 citations · 54 references
MedicineImmunologyInternal MedicineImmunopathologyPulmonologyRenal PathologyFibrosisImmune-mediated Renal DiseaseInterstitial Lung DiseaseInterstitial Lung Disease ImagingRenal DiseaseRenal ImmunopathologyAutoimmune-associated Interstitial Lung DiseaseC3 Complement LevelsInterstitital Lung DiseasePulmonary Fibrosis ProgressionPulmonary Involvement In VasculitisRenal Biopsy FindingsRenal Involvement In VasculitisSystemic Vasculitis
The association between MPO-ANCA-associated vasculitis (AAV) and interstitial lung disease (ILD) has been well established. Pulmonary fibrosis may coexist with, follow, or even precede the diagnosis of AAV, and its presence adversely affects the prognosis. The optimal approach to investigating ANCA in patients with ILD remains a subject of ongoing debate. Here we aim to describe presentation and progression of MPO-ANCA ILD. We conducted a retrospective evaluation of a cohort of individuals diagnosed with MPO-ANCA ILD, with or without accompanying renal impairment, at the Immunology and Cell Therapy Unit, Careggi University Hospital, Florence, Italy, between June 2016 and June 2022. Clinical records, imaging studies, pathologic examinations, and laboratory test results were collected. Among the 14 patients identified with MPO-ANCA ILD, we observed a significant association between MPO-ANCA titers assessed at the time of ILD diagnosis and renal involvement. Renal impairment in these cases often manifested as subclinical or slowly progressive kidney damage. Interestingly, complement C3 deposits were consistently found in all renal biopsy specimens, thereby suggesting the potential for novel therapeutic targets in managing renal complications associated with MPO-ANCA ILD. The presentation of MPO-ANCA vasculitis as ILD can be the first and only clinical manifestation. MPO-ANCA levels at ILD diagnosis could warn on the progression to renal involvement in patients with MPO-ANCA ILD, hence caution is needed because renal disease can be subclinical or smoldering.
54
Avacopan for the Treatment of ANCA-Associated Vasculitis
David Jayne, Peter A. Merkel, Thomas J. Schall et al. · New England Journal of Medicine · 2021 · 969 citations · Full text
Spectrum of Fibrotic Lung Diseases
Marlies Wijsenbeek, Vincent Cottin · New England Journal of Medicine · 2020 · 721 citations